Intracardiac expression of markers of endothelial damage/dysfunction, inflammation, thrombosis, and tissue remodeling, and the development of postoperative atrial fibrillation

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 12, 2011, Pages 2345-2352

  Kaireviciute, D ^a,b   Lip, G Y H ^a   Balakrishnan, B ^a   Uzdavinys, G ^b   Norkunas, G ^b   Kalinauskas, G ^b   Sirvydis, V ^b   Aidietis, A ^b   Zanetto, U ^c   Sihota, H ^c   Maheshwari, M ^c   Blann, A D ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b VILNIUS UNIVERSITY   (Lithuania)

^c CITY HOSPITAL   (United Kingdom)

Author keywords

Atrial fibrillation; Cardiac surgery; Inflammation; Prothrombotic state; Remodeling

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; THROMBOPLASTIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; ENDOCARDIUM; ENDOTHELIAL DYSFUNCTION; FEMALE; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOSIS; TISSUE INJURY;

AGED; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; CORONARY ARTERY BYPASS; ENDOTHELIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MIDDLE AGED; MYOCARDIUM; POSTOPERATIVE COMPLICATIONS; THROMBOSIS;

EID: 82755189885     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04523.x     Document Type: Article

References (38)

1. Kaireviciute D, Aidietis A, Lip GY. Atrial fibrillation following cardiac surgery: clinical features and preventative strategies. Eur Heart J 2009; 30: 410-25.
2. White HD, Antman EM, Glynn MA, Collins JJ, Cohn LH, Shemin RJ, Friedman PL. Efficacy and safety of timolol for the prevention of supraventricular arrhythmias after coronary artery bypass surgery. Circulation 1984; 70: 479-84.
3. Andrews TC, Reimold SC, Berlin JA, Antman EM. Prevention of supraventricular arrhythmias after coronary artery bypass surgery. A meta-analysis of randomized control trials. Circulation 1991; 84: III236-44.
4. Mathew JP, Fontes ML, Tudor IC, Ramsay J, Duke P, Mazer DC, Barash PG, Hsu PH, Mangano DT. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004; 291: 1720-9.
5. Aranki SF, Shaw DP, Adams DH, Rizzo RJ, Couper GS, Vliet MV, Collins JJ, Cohn LH, Burstin HR. Predictors for atrial fibrillation after coronary artery surgery. Circulation 1996; 94: 390-7.
6. Stamou SC, Dangas G, Hill PC, Pfister AJ, Dullum MK, Boyce SW, Bafi AS, Garcia JM, Corso PJ. Atrial fibrillation after beating heart surgery. Am J Cardiol 2000; 86: 64-7.
7. Villareal RP, Hariharan R, Liu BC, Kar B, Lee V-V, Elayda M, Lopez A, Rasekh A, Wilson JM, Massumi A. Postoperative atrial fibrillation and mortality after coronary artery bypass surgery. J Am Coll Cardiol 2004; 43: 742-8.
8. Ahmadi H, Karimi A, Davoodi S, Marzban M, Movahedi N, Abbasi K, Omran AS, Sadeghian S, Abbasi SH, Yazdanifard P, Ardabili MS. 24-hour in-hospital mortality predictions in coronary artery bypass grafting patients. Arch Med Res 2007; 38: 417-23.
9. Likosky DS, Leavitt BJ, Marrin CAS, Malenka DJ, Reeves AG, Weintraub RM, Caplan LR, Baribeau YR, Charlesworth DC, Ross CS, Braxton JH, Hernandez F, O'Connor GT. Intra- and postoperative predictors of stroke after coronary artery bypass grafting. Ann Thorac Surg 2003; 76: 428-35.
10. Psychari SN, Apostolou TS, Sinos L, Hamodraka E, Liakos G, Kremastinos DT. Relation of elevated C-reactive protein and interleukin-6 levels to atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol 2005; 95: 764-7.
11. Conway DS, Buggins P, Hughes E, Lip GY. Prognostic significance of raised plasma levels of IL-6 and C-reactive protein in atrial fibrillation. Am Heart J 2004; 148: 462-6.
12. Thambidorai SK, Parakh K, Martin DO, Shah TK, Wazni O, Jasper SE, Van Wagoner DR, Chung MK, Murray RD. Relation of C-reactive protein correlates with risk of thromboembolism in patients with atrial fibrillation. Am J Cardiol 2004; 94: 805-7.
13. Roldán V, Marin F, Blann AD, Garcia A, Marco P, Sogorb F, Lip GYH. Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. Eur Heart J 2003; 24: 1373-80.
14. Li-Saw-Hee FL, Blann AD, Lip GY. A cross-sectional and diurnal study of thrombogenesis among patients with chronic atrial fibrillation. J Am Coll Cardiol 2000; 35: 1926-31.
15. Lip GY. Does atrial fibrillation confer a hypercoagulable state? Lancet 1995; 346: 1313-14.
16. Gustafsson C, Blombäck M, Britton M, Hamsten A, Svensson J. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke 1990; 21: 47-51.
17. Li-Saw-Hee FL, Blann AD, Goldsmith I, Lip GY. Indexes of hypercoagulability measured in peripheral blood reflect levels in intracardiac blood in patients with atrial fibrillation secondary to mitral stenosis. Am J Cardiol 1999; 83: 1206-9.
18. Hoit BD. Matrix metalloproteinases and atrial structural remodeling. J Am Coll Cardiol 2003; 42: 345-7.
19. Marín F, Roldán V, Climent V, Garcia A, Marco P, Lip GY. Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1? Stroke 2003; 34: 1181-6.
20. Nakano Y, Niida S, Dote K, Takenaka S, Hirao H, Miura F, Ishida M, Shingu T, Sueda T, Yoshizumi M, Chayama K. Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation. J Am Coll Cardiol 2004; 43: 818-25.
21. Kallergis EM, Manios EG, Kanoupakis EM, Mavrakis HE, Arfanakis DA, Maliaraki NE, Lathourakis CE, Chlouverakis GI, Vardas PE. Extracellular matrix alterations in patients with paroxysmal and persistent atrial fibrillation: biochemical assessment of collagen type-I turnover. J Am Coll Cardiol 2008; 52: 211-15.
22. Chen CL, Huang SK, Lin JL, Lai LP, Lai SC, Liu CW, Chen WC, Wen CH, Lin CS. Upregulation of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases in rapid atrial pacing-induced atrial fibrillation. J Mol Cell Cardiol 2008; 45: 742-53.
23. Richter B, Gwechenberger M, Socas A, Zorn G, Albinni S, Marx M, Wolf F, Bergler-Klein J, Loewe C, Bieglmayer C, Binder T, Wojta J, Gössinger HD. Time course of markers of tissue repair after ablation of atrial fibrillation and their relation to left atrial structural changes and clinical ablation outcome. Int J Cardiol 2010; doi:. PMID: 20692054.
24. Kaireviciute D, Blann AD, Balakrishnan B, Lane DA, Patel JV, Uzdavinys G, Norkunas G, Kalinauskas G, Sirvydis V, Aidietis A, Lip GY. Characterisation and validity of inflammatory biomarkers in the prediction of post-operative atrial fibrillation in coronary artery disease patients. Thromb Haemost 2010; 104: 122-7.
25. Altman DG. Practical Statistics for Medical Research. London: Chapman and Hall, 1991.
26. Kirchhof P, Bax J, Blomstrom-Lundquist C, Calkins H, Camm AJ, Cappato R, Cosio F, Crijns H, Diener HC, Goette A, Israel CW, Kuck KH, Lip GY, Nattel S, Page RL, Ravens U, Schotten U, Steinbeck G, Vardas P, Waldo A, et al. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'. Eur Heart J 2009; 30: 2969-77c.
27. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-429.
28. Mukherjee R, Herron AR, Lowry AS, Stroud RE, Stroud MR, Wharton JM, Ikonomidis JS, Crumbley AJ 3rd, Spinale FG, Gold MR. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol 2006; 97: 532-7.
29. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96: 1180-4.
30. Ak K, Akgun S, Tecimer T, Isbir CS, Civelek A, Tekeli A, Arsan S, Cobanoglu A. Determination of histopathologic risk factors for postoperative atrial fibrillation in cardiac surgery. Ann Thorac Surg 2005; 79: 1970-5.
31. Mariscalco G, Engstrom KG, Ferrareze S, Cozzi G, Bruno VD, Sessa F, Sala A. Relationship between atrial histopathology and atrial fibrillation after coronary bypass surgery. J Thorac Cardiovasc Surg 2006; 131: 1364-72.
32. Nakai T, Chandy J, Nakai K, Bellows WH, Flachsbart K, Lee RJ, Leung JM. Histologic assessment of right atrial appendage myocardium in patients with atrial fibrillation after coronary artery bypass graft surgery. Cardiology 2007; 108: 90-6.
33. Blann AD. Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30years. Thromb Haemost 2006; 95: 49-55.
34. Goldsmith I, Kumar P, Carter P, Blann AD, Patel RL, Lip GYH. Atrial endocardial changes in mitral valve disease: a scanning electron microscopy study. Am Heart J 2000; 140: 777-84.
35. Uemura T, Kaikita K, Yamabe H, Soejima K, Matsukawa M, Fuchigami S, Tanaka Y, Morihisa K, Enomoto K, Sumida H, Sugiyama S, Ogawa H. Changes in plasma von Willebrand factor and ADAMTS13 levels associated with left atrial remodeling in atrial fibrillation. Thromb Res 2009; 124: 28-32.
36. Nakamura Y, Nakamura K, Fukushima-Kusano K, Ohta K, Matsubara H, Hamuro T, Yutani C, Ohe T. Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis. Thromb Res 2003; 111(3): 137-42.
37. Fukuchi M, Watanabe J, Kumagai K, Katori Y, Baba S, Fukuda K, Yagi T, Iguchi A, Yokoyama H, Miura M, Kagaya Y, Sato S, Tabayashi K, Shirato K. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J Am Coll Cardiol 2001; 37: 1436-42.
38. Firbas C, Siller-Matula JM, Jilma B. Targeting von Willebrand factor and platelet glycoprotein Ib receptor. Expert Rev Cardiovasc Ther 2010; 8: 1689-701.